Efficacy of 20% Autologous Serum Drops in the Treatment of Corneal Epitheliopathy Associated With Antihypertensive Glaucoma Drops.

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

March 31, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

April 30, 2026

Conditions
Corneal EpitheliopathyGlaucomaCorneal DiseaseDry Eye
Interventions
BIOLOGICAL

20% ASED + AT

Participants receive 20% Autologous Serum Eye Drops prepared by the hospital laboratory from the patients blood, diluted with sterile 0.9% sodium chloride to achieve the desired concentration. These drops are administered 6 times daily in one eye for two months. On top of this intervention is standard artificial tears therapy (Refresh Plus), applied four times daily.

DRUG

0.9% NS + AT

Participants in the placebo group receive eye drops consisting of sterile 0.9% sodium chloride solution, which serves as the placebo. The placebo solution is administered 6 times daily in one eye for two months. Alongside the placebo drops, participants continue with standard artificial tears therapy (Refresh Plus), applied four times daily throughout the study duration.

All Listed Sponsors
lead

Université de Sherbrooke

OTHER

NCT06294015 - Efficacy of 20% Autologous Serum Drops in the Treatment of Corneal Epitheliopathy Associated With Antihypertensive Glaucoma Drops. | Biotech Hunter | Biotech Hunter